Several clinical cases also report that the combination of gefitinib and letrozole (aromatase inhibitor) showed a synergic anti-tumor effect (24) and the administration of estrogen reduced the effect of gefitinib (25) in patient with lung adenocarcinoma concomitantly expressing ER and EGFR. The gene discussed is CYP19A1; the disease is neoplasm.